Cognizant cleared expectations in the third quarter, though not by much, and the forward commentary carried more weight than the beat. Adjusted EPS of $1.49 topped the $1.46 consensus and the $1.47 Earnings Whisper number by 1.4% and rose 7.2% year over year. Revenue of $5.664 billion edged past the $5.65 billion consensus by 0.2% and grew 4.6% (4.8% in constant currency). On the surface, top-line growth accelerated for a third straight quarter, from 3.9% in Q1 to 4.1% in Q2 to 4.8% now. That is the central tension. The quarter looked better than the business underneath it, and management cut the top end of full-year revenue guidance for the second consecutive quarter. The new Q4 outlook implies organic growth slowing to roughly 2% by year-end.

The quality of the beat deserves scrutiny. Recent acquisitions, primarily 3Cloud and Astria, added about 210 basis points to Q3 growth. Low-margin resale of third-party products under the integrated-offerings strategy added another 190 basis points. Together those two sources account for most of the reported 4.6%. The segment picture is lopsided. Financial Services grew 12.3% in constant currency, its third straight double-digit quarter, and Communications, Media and Technology grew 10.7%. In CMT, however, acquisition (875 basis points) and resale (600 basis points) contributions exceeded the segment's entire reported growth. Health Sciences slipped 0.9% and Products and Resources fell 0.8%. On earnings, adjusted net income of $670 million was actually slightly below last year's $675 million. The 7.2% per-share gain came from a diluted share count that fell to 450 million from 487 million. GAAP EPS of $1.39 versus $0.56 is flattering only because last year's quarter absorbed a $390 million one-time tax charge. GAAP operating margin fell 60 basis points to 15.4% on $51 million of Project Leap restructuring costs.

Where Cognizant genuinely delivered was profitability. Adjusted operating margin reached 16.3%, up 30 basis points year over year. That marks the seventh consecutive quarter of expansion and the highest level in four years. Management narrowed full-year margin guidance to about 16.1%, trimmed the tax-rate outlook to roughly 25%, and lowered the expected Project Leap cost to $180 million to $250 million from $230 million to $320 million, crediting reskilling and redeployment. The AI story also gained substance:

• More than 50% of code is now AI-assisted, up from about 40% last quarter.
• AI engagements rose to 8,500 from 8,000.
• New and expansion work climbed to roughly 60% of bookings.
• AI-tailwind service lines, about 40% of the business, are growing at two to three times the organic rate.

The demand side is where bears have legitimate ammunition. Full-year constant-currency revenue guidance is now 4.0% to 4.4%, down from 4% to 5.5% in Q2 and 4% to 6.5% in February. Q4 guidance of 3.2% to 4.7% constant-currency growth sits below what the Street expected. Management cited three pressures:

• macro uncertainty weighing on discretionary spending in healthcare and consumer-facing sectors;
• Medicaid and Medicare regulatory uncertainty;
• heavier Q4 furloughs than assumed, plus lower resale contribution.

Bookings fell 7% in the quarter. Trailing 12-month bookings growth decelerated to 4%, from 5% in Q2 and 11% in Q1, with only three large deals versus seven in each of the prior two quarters, and annual contract value declined modestly. Project Leap savings landed at about $200 million, the low end of the prior $200 million to $300 million range. Cash quality also softened. Q3 free cash flow of $925 million rebounded from Q2 but trailed last year's $1.16 billion, and DSO rose five days to 89. Long-term debt has tripled to $1.55 billion since year-end after acquisitions and $1.9 billion of year-to-date buybacks.

The market setup is more complicated than the surprise implies. Investor sentiment swung meaningfully from slightly negative (-0.06) after the July report to moderately positive (0.23) heading into this one. Shares rallied 26.9% from the post-July open of $52.31 to $66.36, trading nearly 12% above the 200-day moving average. Price, sequential-growth and AVWAP trend readings were positive. Yet the stock had already retreated about 10% from its October 22 inter-earnings high of $73.92 before the release, suggesting some of the enthusiasm had begun to fade. Investors arriving with improved expectations now face a guidance cut and a decelerating organic exit rate, not the acceleration the headline growth figure suggested.

The bottom line is that Cognizant is executing well on what it controls: margins, cost programs, capital return and AI delivery capability. The revenue engine underneath is weakening. Acquisitions, third-party resale and buybacks are carrying much of the headline growth, while bookings momentum and the Q4 outlook point to roughly 2% organic growth. Until Financial Services strength broadens and bookings reaccelerate, the record margin is the quarter's strongest feature, not proof that demand has turned.